Effect of number of human papillomavirus vaccine doses on guideline adherent cervical cytology screening among 19-26 year old females

Preventive Medicine

Volumn 88, Issue , 2016, Pages 134-139

  Hirth, Jacqueline M ^a   Lin, Yu Li ^a   Kuo, Yong Fang ^a   Berenson, Abbey B ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

Cervical intraepithelial neoplasia; Health care providers; Human papillomavirus; Papanicolaou smear; Papanicolaou test; Papillomavirus vaccines

Indexed keywords

ADULT; ARTICLE; CANCER SCREENING; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HUMAN; INSURANCE; MAJOR CLINICAL STUDY; PAPANICOLAOU TEST; PAPILLOMAVIRUS INFECTION; PATIENT COMPLIANCE; PATIENT EDUCATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; UTERINE CERVIX CANCER; UTERINE CERVIX CYTOLOGY; UTERINE CERVIX DYSPLASIA; VACCINATION; YOUNG ADULT; ATTITUDE TO HEALTH; CERVICAL INTRAEPITHELIAL NEOPLASIA; EARLY CANCER DIAGNOSIS; GENERAL PRACTITIONER; PAPILLOMAVIRUS INFECTIONS; PROCEDURES; PROTOCOL COMPLIANCE; UTERINE CERVICAL NEOPLASMS; UTILIZATION; VAGINA SMEAR;

WART VIRUS VACCINE;

ADULT; CERVICAL INTRAEPITHELIAL NEOPLASIA; EARLY DETECTION OF CANCER; FEMALE; GUIDELINE ADHERENCE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; PAPANICOLAOU TEST; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PHYSICIANS, PRIMARY CARE; RETROSPECTIVE STUDIES; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 84963847245     PISSN: 00917435     EISSN: 10960260     Source Type: Journal    
DOI: 10.1016/j.ypmed.2016.04.004     Document Type: Article

References (27)

1. ACOG Committee on Practice ACOG practice bulletin clinical management guidelines for obstetrician-gynecologists. Obstet. Gynecol. 2003, 102(2):417-427.
2. ACOG Committee on Practice Bulletins-Gynecology ACOG Practice Bulletin no109: cervical cytology screening. Obstet. Gynecol. 2009, 114(6):417-427.
3. ACOG Committee on Practice Bulletins-Gynecology Screening for cervical cancer. Obstet. Gynecol. 2012, 120(5):1222-1238.
4. Advisory Committee on Immunization Practices (ACIP) FDA licensure of bivalant human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP). MMWR 2010, 59(20):626-629.
5. Armitage C.J., Conner M. Efficacy of the Theory of Planned Behavior: a meta-analytic review. Br. J. Soc. Psychol. 2001, 40:471-499.
6. Block S.L., Nolan T., Sattler C., Barr E., Giacoletti K.E.D., Marchant C.D., Castellsagué X., Rusche S.A., Lukac S., Bryan J.T., Cavanaugh P.F., Reisinger K.S. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics 2006, 118(5):2135-2145.
7. Bulletins-Gynecology.ACoP ACOG practice bulletin no109: cervical cytology screening. Obstet. Gynecol. 2009, 114(6):1409-1420.
8. Feikema S.M., Klevens M., Washington M.L., Barker L. Extraimmunization among US children. JAMA 2000, 283(10):1311-1317.
9. Hariri S., Johnson M.L., Bennett N.M., Bauer H.M., Park I.U., Schafer S., Niccolai L.M., Unger E.R., Markowitz L.E., HPV-IMPACT Working Group Population-based trends in high-grade cervical lesions in the early human papillomavirus vaccine era in the United States. Cancer 2015, 121(16):2775-2781.
10. HEDIS HEDIS 2012 Technical Specification Vol IV 2012, (Washington DC).
11. HEDIS HEDIS 2013 Technical Specification Vol V 2013, (Washington DC).
12. Hildesheim A., Herrero R., Wacholder S., Rodríguez A.C., Solomon D., Bratti M.C., Schiller J.T., González P., Dubin G., Porras C., Jiménez S., Lowy D.R. Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA 2007, 298(7):743-753.
13. Hirth J.M., Tan A., Wilkinson G.S., Berenson A.B. Completion of the human papillomavirus vaccine series among insured females between 2006 and 2009. Cancer 2012, 118:5623-5629.
14. Hirth J.M., Tan A., Wilkinson G.S., Berenson A.B. Compliance with cervical cancer screening and human papillomavirus testing guidelines among insured young women. Am. J. Obstet. Gynecol. 2013, 209(3):200.e201-200.e207.
15. Hofman R., van Empelen P., Richardus J.H., de Kok I.M.C.M., de Koning H.J., van Ballegooijen M., Korfage I.J. Predictors of HPV vaccination uptake: a longitudinal study among parents. Health Educ. Res. 2014, 29(1):83-96.
16. Kepka D., Smith A., Zeruto C., Yabroff K.R. Is provider type associated with cancer screening and prevention: advanced practice registered nurses, physician assistants, and physicians. BMC Cancer 2014, 14(233).
17. Klabunde C.N., Brown M.-B., Rachel W.M.C., Thompson T., Plescia M., King S.C. Cancer screening - United States, 2010. MMWR 2012, 61(3):41-45.
18. Langsjoen J., Goodell C., Castro E., Thomas J., Kuehl T.J., Wehbe-Janek H., Hinsky M. Improving compliance with cervical cancer screening guidelines. Proc. (Baylor Univ. Med. Cent.) 2015, 28(4):450-453.
19. Meissner H.I., Yabroff K.R., Dodd K.W., Leader A.E., Ballard-Barbash R., Berrigan D. Are patterns of health behavior associated with cancer screening?. Am. J. Health Promot. 2009, 23(3):168-175.
20. Perry R., Rankin K., Yu M.C., Harwood B. Factors associated with human papillomavirus vaccination completion on a catch-up schedule. Obstet. Gynecol. 2014, 124(1):76-81.
21. Price R.A., Koshiol J., Kobrin S., Tiro J.A. Knowledge and intention to participate in cervical cancer screening after the human papillomavirus vaccine. Vaccine 2011, 29:4238-4243.
22. Rahman M., McGrath C.J., Hirth J.M., Berenson A.B. Age at HPV vaccine initiation and completion among US adolescent girls: trend from 2008 to 2012. Vaccine 2015, 33(5):585-587.
23. Rodríguez A.C., Solomon D., Herrero R., Hildesheim A., González P., Wacholder S., Porras C., Jiménez S., Schiffman M. Impact of human papillomavirus vaccination on cervical cytology screening, colposcopy, and treatment. Am. J. Epidemiol. 2013, 178(5):752-760.
24. Saslow D., Solomon D., Lawson H.W., Killackey M., Kulasingam S.L., Cain J., Garcia F.A.R., Moriarty A.T., Waxman A.G., Wilbur D.C., Wentzensen N., Downs L.S., Spitzer M., Moscicki A.-B., Franco E.L., Stoler M.H., Schiffman M., Castle P.E., Myers E.R. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J. Clin. 2012, 62:147-172.
25. Sauer A.G., Jemal A., Simard E.P., Fedewa S.A. Differential uptake of recent Papanicolaou testing by HPV vaccination status among young women in the United States, 2008-2013. Cancer Epidemiol. 2015, 39(4):650-655.
26. U.S.Preventive Services Task Force Final recommendation statement: cervical cancer: screening 2014, (2015 (Jan 15)).
27. Williams W.W., Lu P.-J., Saraiya M., Yankey D., Dorell C., Rodriguez J.L., Kepka D., Markowitz L.E. Factors associated with human papillomavirus vaccination among young adult women in the United States. Vaccine 2013, 31(28):2937-2946.